Immunovaccine Inc. (TSX-V: IMV) July 2011

Transcription

1 Immunovaccine Inc. (TSX-V: IMV) July 2011

2 2 Forward Looking Statements This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans or objectives will be achieved. Actual results may differ materially from those expressed or implied by the forward-looking information set forth in this document due to risks and uncertainties affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. The forward-looking statements in this document are based on a number of assumptions which may prove to be incorrect, including assumptions concerning general business and economic conditions, positive clinical trials and the availability of financing. Immunovaccine assumes no responsibility to update forward-looking statements in this document.

3 3 Where It All Began Immunovaccine emerged from Dalhousie University Developed successful contraceptive vaccine to control the seal population The vaccine delivery system was proven highly effective

4 4 DepoVax TM Immunovaccine s Delivery Platform Patented vaccine delivery enhancement platform Uses liposomes to bring active vaccine components into the oil depot Surrounded by significant immune response Fast, strong and long-lasting immune responses in as little as ONE DOSE Broad international patent coverage, US, EU, Asia, Aus. Broad market applications for infectious disease and therapeutic cancer vaccines DepoVax TM -based vaccine Broadly tested

5 5 DepoVax TM & Therapeutic Cancer Today s chemotherapy cancer treatments are extremely toxic and non-specific In preclinical studies DepoVax -based cancer vaccines eradicated 100% of tumors with a single dose Published peer-reviewed scientific publications including the Journal of Immunotherapy, April 2010 Evaluated by International Cancer Experts: Dr. Eli Gilboa Dr. Rong-fu Wang Dr. W. Martin Kast MRI slices courtesy of IBD/NRC Atlantic

6 6 Business Strategy - Capitalize on broad patents License for Animal health applications to drive human health business - (4 commercial license agreements with Pfizer) Partner out DepoVax to provide enhanced delivery to other company s vaccines - The DepoVax challenge Develop our own vaccine products - DPX-0907 and DPX-Survivac

7 7 License Animal Opportunities to Drive Human Health Business Signed 4 Deals with Pfizer Animal Health Pfizer funding all product development whilst paying milestones & royalties from vaccine sales The licenses with Pfizer reduce the risk profile for our investors by providing near-term revenues and validation of our patents Immunovaccine is in discussions to license its technology for further animal health vaccines Animal Health

8 8 w DepoVax Challenge Enhance your vaccine with DepoVax vaccine delivery

9 The DepoVax Challenge Partners World Leading Institutions 9

10 The DepoVax Challenge - Global Corporate Partnerships 10

11 11 Clinical Pipeline Indication Preclinical Phase I Phase II Phase III DPX-0907 DPX-Survivac

12 12 w DPX-0907 Therapeutic cancer vaccine targeting breast, ovarian & prostate cancer

13 13 DPX-0907 Vaccine - Completion of Phase I Clinical Study DPX-0907 Vaccine = 7 antigens + DepoVax Treating patients with advanced stage breast, ovarian & prostate cancer DPX-0907 vaccine designed to target major cancer cell pathways First-in-man for a DepoVax -based product Phase I: Safety established in 23 patients

14 14 DPX-0907 Vaccine - Summary of Results Well tolerated No vaccine related serious adverse events No dose limiting toxicities Vaccine elicited antigen-specific immune responses: activated T cells were polyfunctional Significant win for DPX-0907 as it establishes a safety profile for the DepoVax TM platform. Business development is pursuing opportunities to take DPX-0907 forward

15 15 w DPX-Survivac Vaccine applicable to 9 cancer indications

16 16 w DPX-Survivac Survivin-based vaccine Licensed from Merck KGaA DPX-Survivac targets survivin Cancer cells need survivin to survive Survivin ranked as top 25 promising cancer antigens by the National Cancer Institute DepoVax - a proven technology DPX-Survivac - a vaccine with broad market potential, survivin is over-expressed in 9 cancers

17 17 w Immune Response SFU (per 200,000 cells) DPX-Survivac - Development Timeline Q4, 2010: signed license with Merck KGaA Preclinical Study DPX-Survivac Q Q2 2011: formulation development Animal Proof of concept for DPX-Survivac Preclinical safety studies Filed IND June 17, 2011: FDA approves Phase I/II clinical trial proposal DPX-Survivac Survivac Q4 2011; start of DPX-Survivac clinical trial

18 18 w DPX-Survivac For Therapy of Ovarian Cancer Cancer Surgery Vaccinate Monitor Discovered Chemo Returns

19 19 w DPX-Survivac FDA approves IMV s Phase I/II clinical trial proposal Vaccine Preclinical Phase I Phase II Phase III DPX-Survivac Saves time, eliminates regulatory risk

20 20 Management Marc Mansour, Ph.D., Chief Operating Officer & Chief Science Officer Kimberly Stephens, C.A., Chief Financial Officer Vicki Morgan, Director of Business Development Jennifer Cameron, Director of Communications Key staff consultants leading Clinical & Business development Dr. Neil Berinstein, Clinical Irene Clement, Regulatory Paul Kirkconnell, Business Development

21 21 Board Members Albert Scardino, Board Chair Dr. William Cochrane, Board member Wade K. Dawe, Board member James Hall, C.A., Board member Brad Thompson, Ph.D. Board member Kimberly Stephens, C.A., Board member

22 22 w Immunovaccine Capital Position Total shares issued & outstanding 53.9m Year high low $ $1.45 Market Cap $29.7m Average volume 35,000 Available Cash Resources (Mar. 31, 2010) $13m o $2.9m non-dilutive gov t funding Average burn rate/month $0.65m

23 23 Immunovaccine Highlights Immunovaccine s patented DepoVax platform meets the increasing market need for premium vaccines, both for cancer and infectious disease Immunovaccine s strategy: License, Partner, Develop Immunovaccine is reducing its risk and increasing company value through animal health license agreements Research partnerships are anticipated to progress to commercial relationships Currently advancing company controlled cancer vaccine pipeline: DPX-0907 and DPX-Survivac Sufficient capital position to complete DPX-0907 Phase I & to fund the Phase I for DPX-Survivac DPX-Survivac - Proof of concept in ovarian; applicable to other cancers with broad market potential

24 24 Upcoming Milestones Q Q Q Q Q Q Q Q Upcoming milestones include: Manufacturing the clinical batch of DPX-Survivac Patient recruitment for Phase I trial of DPX-Survivac Initiation of a Phase I clinical trial for DPX-Survivac Potential research and license agreements Publishing Phase I final results for the DPX-0907

25 Immunovaccine Inc. (TSX-V: IMV) July 2011